Optimizing Heart Failure Outcomes with Intravenous Iron: Adaptive Approaches for Effective Diagnosis and Treatment of Iron Deficiency in HFrEF
This timely and dynamic educational activity will begin with a foundational circumscription of iron deficiency (ID) pathophysiology and clinical gravity in heart failure (HF), particularly in heart failure with reduced ejection fraction (HFrEF), as well as the impact of elevated hepcidin on iron supplementation strategies. An expert-led exploration of clinical trial data for intravenous (IV) iron therapies in HF and recently-updated expert consensus HF management guidelines will follow, with emphasis on the emerging role of IV iron on improvement of patient functional capacity, quality of life, and hard clinical endpoints in HFrEF. Finally, activity attendees will apply all they’ve learned in an interactive, case-based section that will highlight the improved safety and efficacy profiles of next-generation IV iron products, the importance of total dose infusions (TDIs), and the practical utility of digitalized checklists to ensure adherence to guideline-directed medical therapy (GDMT) in HF, of which IV iron is quickly becoming a standard pillar of care.
Cardiologists and key members of their interprofessional and multidisciplinary care teams who manage patients with heart failure.
Registration for the 2022 HFSA Annual Scientific Meeting and an official name badge are required to attend this symposium.
- Summarize the basic principles of iron metabolism and absorption, with a focus on how these principles apply to treatment of iron deficiency (ID) in heart failure (HF).
- Distinguish between HFrEF and HFpEF in terms of clinical presentation, diagnosis, and treatment standards.
- Review the pivotal role of hepcidin in ID pathophysiology, especially in a hyperinflammatory condition like HF, irrespective of the presence or absence of comorbid anemia.
- Recognize the robust impact of comorbid ID and HF, and describe the prognostic manifestations of ID on patient functional capacity, quality of life, and HF morbidity and mortality outcomes.
- Evaluate the essential utility of serum ferritin and transferrin saturation (TSAT) as diagnostic laboratory indices for ID, and implement the “diagnose, treat-to-target, and rapid reassessment cycle” into practice.
- Differentiate the practical distinctions between functional and absolute iron deficiency in the setting of HF.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and identify pivotal data readouts that have influenced current practice and consensus HF guideline statements (ESC and ACC/AHA/HFSA).
- Understand how the innovative nanoparticle design of next-generation IV iron products improves upon the safety profiles of earlier generation products, with anaphylaxis rates as low as 0.1%.
- Use a case-based format to analyze how pro-inflammatory cytokines and elevated hepcidin levels impact the comparative clinical utility of oral vs IV iron supplementation modalities in HFrEF.
- Compare and contrast FDA-approved IV iron agents, including updated label indications and dosing regimens.
- Design innovative, evidence-supported clinical tools that can interface with institutional EHRs, such as diagnostic algorithms, digitalized checklists to promote HF GDMT, and Ganzoni’s formula to determine iron repletion dosages.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from American Regent.
10 min Welcome
20 min Heart Failure Disease State Review: The Pathophysiology and Clinical Gravity of Concomitant Iron Deficiency
25 min A New Standard in Heart Failure Management: Ushering in the Era of Intravenous Iron as a Pillar of Care
25 min Cardiology Catalysts: Real-world Strategies for Closing the Iron Deficiency Chasm in HFrEF
10 min Q&A/Panel Discussion
Javed Butler, MD, MPH, MBA (Activity Chair)
Patrick H Lehan Chair in Cardiovascular Research
Professor and Chairman, Department of Medicine
University of Mississippi Medical Center
Stefan D. Anker, MD, PhD
Professor of Cardiology and Cachexia Research
Department of Cardiology
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair and Professor of Medicine
Associate Provost of Faculty Affairs
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Assoc. Director, Cardiovascular Research Institute
Vice-Chair of Medicine, Baylor College of Medicine
Medicine Chief, DeBakey VA Medical Center
Muthiah Vaduganathan, MD, MPH
Instructor in Medicine
Harvard Medical School
Brigham and Women’s Hospital
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Javed Butler, MD, MPH, MBA–has disclosed that he is on the Speakers Bureau for AstraZeneca, Boehringer Ingelheim, Novartis, and Vifor. He is also an advisor or consultant to Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, CVRx, G3, Impulse Dynamics, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Pfizer, Roche, and Vifor Pharma.
Stefan D. Anker, MD, PhD–has disclosed that he receives grants from Abbott and Vifor (International). He is also an advisor or consultant to ASTRA, Bayer, Boehringer Ingelheim, Cardiac Dimension V-Wave, Novartis, Occlutech, and Vifor Pharma.
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP–has disclosed that she is an advisor or consultant to Amgen, AstraZeneca, and Vifor Pharma. She was an advisor or consultant to Baxter, Bristol Myers Squibb, Sanofi-Aventis, and scPharmaceuticals. She also receives other financial or material support from Abbott, Cardurion, and Liva Nova.
Muthiah Vaduganathan, MD, MPH–disclosures to come.
Information to come.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, this activity has been planned and implemented by the Heart Failure Society of America and Creative Educational Concepts. The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.